国际经济与贸易学院知识库

      中国经济的发展带动了人们生活水平的提高的同时促进了医疗器械企业的 发展，医疗资源的下沉，人口老龄化等原因进一步扩大了对医疗器械产品的需求。 但是，由于中国的医疗器械行业起步较晚，整体水平落后于发达国家，难免在全 球市场的激烈竞争中处于劣势，尤其在中高端产品的赛道上，飞利浦等国外品牌 表现强劲，几乎垄断了国内中高端医疗器械市场。迈瑞医疗作为中国最大的医疗 器械供应商，近两年打破了我国中高端医疗器械长期被外国品牌垄断的现象。但 是，相较于国际头部医疗器械企业，其仍然面临绩效水平相对较低，中高端市场 份额占比相对较小的局面。为了解决当前我国中高端医疗器械产品对外依赖程度 高的问题，提高中国医疗器械行业整体水平，本文以迈瑞医疗为研究对象，从企 业价值链的角度出发，提出改进企业绩效的策略，为医疗器械企业发展建言献策。

      本文首先对迈瑞医疗经营概况与企业价值链现状进行了阐述，明确了迈瑞在 一众中国医疗器械企业中营收最高，企业价值链各环节铺建完备，但是与国际头 部企业相比绩效水平仍差距较大的境况。因此，为进一步提升迈瑞的企业绩效加 强国际竞争，本文以迈瑞企业价值链各环节指标为解释变量，综合绩效为被解释 变量进行岭回归分析。实证结果表明迈瑞企业价值链的四个环节（研发、生产、 销售、售后）均对综合绩效有正向影响关系，这说明迈瑞对企业价值链加大投入 或优化运行流程能够提升企业综合绩效。在此基础上，本文选取综合绩效水平较 高的飞利浦医疗与迈瑞医疗在企业价值链环节在对比，探究迈瑞医疗与国际头部 医疗器械企业在企业价值链方面的差异，研判迈瑞医疗在企业价值链各环节的改 进方式以提升企业绩效。 研究表明：迈瑞医疗需要在研发环节提高研发产出效率；在生产环节优化生 产结构；在销售环节需加大资金投入，尤其是增加销售人员激励措施的奖励；售 后环节需加强售后产品信息反馈的职能。上述措施在提高迈瑞经营绩效的同时也 为中国医疗器械企业如何改进企业价值链加强竞争力提供了参考。

      The development of China's economy has led to an improvement in people's living standards and at the same time promoted the development of medical device companies. The sinking of medical resources and an ageing population have further expanded the demand for medical device products. However, due to the late start of China's medical device industry, the overall level of the industry lags behind that of developed countries and is inevitably at a disadvantage in the fierce competition in the global market, especially in the track of mid- to high-end medical products, where foreign brands such as Philips perform strongly and almost monopolise the domestic mid- to high-end medical device market. Mindray Medical, as the largest medical device supplier in China, has broken the long-standing monopoly of foreign brands in China's mid- to high-end medical devices in the last two years. However, it still faces a relatively low level of performance and a relatively small share of the mid- to high-end market compared to international headline medical device companies. In order to solve the current problem of high foreign dependence of China's mid- and high-end medical device products and to improve the overall level of China's medical device industry, this paper takes Mindray Medical as the research object and proposes strategies to improve corporate performance from the perspective of the corporate value chain, in order to provide suggestions for the development of medical device companies.

      The paper begins with an overview of Meizu Medical's operations and the current state of its corporate value chain. It is clear that Meizu has the highest revenue among Chinese medical device companies, and that its corporate value chain is well established, but its performance level is still far below that of international leaders. Therefore, in order to further improve Mindray’s corporate performance and strengthen international competition, this paper conducts a ridge regression analysis using the indicators of Mindray’s corporate value chain as the explanatory variables and comprehensive performance as the explanatory variables. The empirical results show that all four links of the value chain (R&D, production, sales and after-sales) have a positive effect on the overall performance, which indicates that Mindray can improve its overall performance by increasing its investment in the value chain or optimising its operational processes. Based on this, this paper compares Philips Medical, which has a high level of overall performance, with Mindray Medical in the enterprise value chain, to investigate the differences between Mindray Medical and international leading medical device companies in the enterprise value chain, and to determine how Mindray Medical can improve its enterprise performance in each link of the enterprise value chain.

      The study shows that Mindray Medical needs to improve the efficiency of its R&D output in the R&D segment; optimise its production structure in the manufacturing segment; invest more money in the sales segment, especially to increase incentives for sales staff; and strengthen its post-sales product feedback function in the after-sales segment. The above measures will improve Mindray's business performance and also provide a reference for how Chinese medical device companies can improve their corporate value chain to strengthen their competitiveness.